TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stool characteristics score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colon cleanness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: stability and alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal reflux events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma fasting adiponectin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of HMW adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants who signed organ donor cards
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage who discussed their donation intentions with family members
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean percentage of participants' family members who signed organ donor cards
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Heart failure symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADF (Average Dynamic Force)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMJ (Countermovement Jump)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: benefit from dignity therapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean arterial blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isoflurane usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about colposcopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rate (cr + pr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of health and life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Laryngospasm incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Mean discharge time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Willingness to participate in exercise intervention
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Median time to peak plasma concentration (t(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of saroglitazar
Endpoint domain: Adverse events/effects
Primary endpoint: remission rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: New compression fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in social and family functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: DAS28‐CRP < 2.6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative pharyngolaryngeal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Large artery elastic wall properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate (HR) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gastric ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: Oesophageal erosions
Endpoint domain: Adverse events/effects
Primary endpoint: Gastroduodenal erosion scores
Endpoint domain: Adverse events/effects
Primary endpoint: overall volume consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Colorectal cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: higher function scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: less pain on activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum NSE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mental HRQL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mood symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean fibrinogen level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: units of cryoprecipitate transfused
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: total donor exposure to blood products
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of clinically definite MS (CDMS)
Endpoint domain: Mortality/survival
Primary endpoint: Postprandial glucose nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuroglycopenic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of potentially inappropriate medications (PIM) at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of drug-drug interactions (DDI) at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rates at 12-month follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of re-hospitalization at 12-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of TTN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma levels of neurohormones and extracellular matrix modulators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma acetate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma bicarbonate values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-6 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interference with daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of spontaneous conversion to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence rate of atrial fibrillation at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lacrimal flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Range of motion (ROM) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Contrast medium amount used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful passage of the culprit stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight-for-height z score > -2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse or death
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in all cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: MSP-119 seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean semi-quantitative antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CLINIC-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linkage of positive STI test results with HIV testing within 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak arterial concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial pain relief rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acid regurgitation relief rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days of defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of defecations per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum FGF23 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum phosphorus concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Short Physical Performance Battery (SPPB) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-minute walking test (6 MW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective perception of incontinence control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Achievement of LDL-C goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported e-cig use in times per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein expression of VEGF in umbilical cord cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle activation of lower limb muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial volume (ICV) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain tumor volume (BTV) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White matter hyperintensity volume (WMHV) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐prandial hyperglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serious adverse events (SAE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: mean weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sitting height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of clinically acceptable surgical conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients who exhibited vocal cord movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Markers of systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean extraction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: past pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: anticipated past pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: onset of motor paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ambulatory times
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative malaria case incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PCR-determined parasite prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum total cholesterol (TC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum apolipoprotein B (ApoB) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Psychosocial Independence
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Physical Independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gastric mucosal perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arterial lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiac noradrenaline release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seizure-frequency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: diastolic cardiac function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: regression of left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NRS scores difference from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of substantial responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of substantial/moderate responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free phenytoin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum velocity of phenytoin metabolism (Vmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum enhancement values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to reach 100 HU opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T(2) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean HAM-D-17 scores at endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates of 48% based on > or = 50% reduction in HAM-D-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aorta-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Response rate of screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Positive predictive value for cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: maximal exogenous CHO oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Dose Intensity (RDI)
Endpoint domain: Resource use
Primary endpoint: emotional burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weight-for-age-and-sex z score (wfaszs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI-adjusted-for-age-and-sex z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height-for-age-and-sex z score (hfaszs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year prevalence of DI in dermatology outpatients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: point prevalence of DI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inner diameter of atria sinistrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in diameter of left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cognitive change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GCF concentrations of angiogenic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Melasma Area Severity Index (MASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: melanin indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cognitive deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of AKP
Endpoint domain: Mortality/survival
Primary endpoint: Probability of being a nonresponder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDV (End-Diastolic Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ESV (End-Systolic Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perfusion scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: provider burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rate after ICT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scale for Assessment of Negative Symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in correct naming
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate in mixed AV patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reduction in VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of people with good glycemic control (A1c<7%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving three or more quality improvement goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine consumption after 48 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild motor block
Endpoint domain: Adverse events/effects
Primary endpoint: Prolonged postoperative opioid prescriptions
Endpoint domain: Adverse events/effects
Primary endpoint: Total and differential white blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: decreased scores of visual analogue scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased doses of carbamazepine required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Opioid withdrawal suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC function score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving HbA1c levels below 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients achieving FPG levels of less than 7.8 mmol/L (140 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: abortion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Success rate of IANB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum OPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin resistance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACh response (forearm blood flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physicians' responsiveness to prompts
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Thickness of gastrocnemius medialis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in size of calculi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area of skin with surgically-induced mechanical hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area of heat-induced secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain during cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy for shape identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycling power at first and second ventilatory thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of 1,25(OH)2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of high-density lipoproteins (HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cervical cancer mortality
Endpoint domain: Mortality/survival